# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-216759
Filing Date
2026-05-11
Accepted
2026-05-11 16:08:46
Documents
65
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | sepn-20260331.htm iXBRL | 10-Q | 2663765
2 | EX-10.1 | sepn-ex10_1.htm | EX-10.1 | 38418
3 | EX-31.1 | sepn-ex31_1.htm | EX-31.1 | 19979
4 | EX-31.2 | sepn-ex31_2.htm | EX-31.2 | 19378
5 | EX-32.1 | sepn-ex32_1.htm | EX-32.1 | 17253
6 | GRAPHIC | img191903475_0.jpg | GRAPHIC | 216123
| Complete submission text file | 0001193125-26-216759.txt |  | 10307383

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | sepn-20260331.xsd | EX-101.SCH | 1232481
69 | EXTRACTED XBRL INSTANCE DOCUMENT | sepn-20260331_htm.xml | XML | 1768842

Mailing Address 250 EAST GRAND AVENUE, SUITE 65 SOUTH SAN FRANCISCO CA 94080
Business Address 250 EAST GRAND AVENUE, SUITE 65 SOUTH SAN FRANCISCO CA 94080 650-338-3533
Septerna, Inc. (Filer) CIK: 0001984086 (see all company filings)

EIN.: 843891440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42382 | Film No.: 26963240
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)